M. Bilal Abid: Cell and Gene Therapies are Transforming Patient Care
M. Bilal Abid, Clinical Fellow, Hematology/Oncology at The University of Texas Health Science Center at Houston, shared a post on LinkedIn about a paper by Frederick L. Locke et al. published in Blood:
“Cell and gene therapies are transforming patient care. While all other factors related to cell therapy – cell sources, engineering, genetic modifications, need for enhancements, and lymphodepletion – impact efficacy and safety, the manufacturing platform impacts access.
This, at least in part, contributes to access disparities and outcomes as we showed in one of our studies with axi-cel (CD19+ CAR-T). Blacks had a shorter survival (PFS) than other races, possibly related to barriers to access (Graphic below with link).
Happy to end another day in the lab with point of care manufacturing and doing our part to curb disparities!”
Title: Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Authors: Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson, Armin Ghobadi, Sairah Ahmed, David B. Miklos, Miguel-Angel Perales, Javier Munoz, Warren B. Fingrut, Martina Pennisi, Jordan Gauthier, Mazyar Shadman, Lohith Gowda, Abu-Sayeef Mirza, Muhammad Bilal Abid, Sanghee Hong, Navneet S. Majhail, Mohamed A. Kharfan-Dabaja, Arushi Khurana, Talha Badar, Yi Lin, N. Nora Bennani, Megan M. Herr, Zhen-Huan Hu, Hai-Lin Wang, Anjani Baer, Elande Baro, Harry Miao, Clare Spooner, Hairong Xu, Marcelo C. Pasquini
You can read the Full Article in Blood.
More posts featuring M. Bilal Abid.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023